Background/aims: Prior studies have shown that patients with dementia are at risk of receiving insufficient treatment for pain after a hip fracture. We therefore hypothesized that elderly hip fracture patients with dementia received less postoperative pain treatment than those without dementia.
Method: All patients (age ≥65 years) who had been operated on for a hip fracture in the Copenhagen University Hospital region in 2009 were included. Data about analgesic use for the first 72 h after surgery were acquired from the hospitals' electronic medication system and linked with information about dementia, comorbidity, and prior drug use.
Results: A total of 1,507 patients were included, of which 296 (19.6%) suffered from dementia. Both groups were equally likely to receive paracetamol and opioids. Patients with dementia received lower doses of oral morphine equivalents during the first [dementia vs. no dementia: 29.0 (26.4-31.8) vs. 34.7 (33.1-36.4) mg, p = 0.001] and second [27.8 (25.4-30.5) vs. 31.2 (29.9-32.4) mg, p = 0.019] but not on the third postoperative day (p = 0.10).
Conclusion: The lower doses of opioids may reflect uncertainty about how to treat pain patients with dementia. Further guidance is needed, as inadequate treatment of pain may have adverse consequences.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000444704 | DOI Listing |
Co-existing neuropathological comorbidities have been repeatedly reported to be extremely common in subjects dying with dementia due to Alzheimer disease. As these are likely to be additive to cognitive impairment, and may not be affected by molecularly-specific AD therapeutics, they may cause significant inter-individual response heterogeneity amongst subjects in AD clinical trials. Furthermore, while originally noted for the oldest old, recent reports have now documented high neuropathological comorbidity prevalences in younger old AD subjects, who are more likely to be included in clinical trials.
View Article and Find Full Text PDFPhys Ther Res
November 2024
Graduate School of Rehabilitation Science, Osaka Metropolitan University, Japan.
Chronic kidney disease (CKD) is a recognized risk factor for cognitive impairment and dementia. Unfortunately, the number of patients with both CKD and dementia has been steadily increasing with the aging patient population. Therapeutic management and clinical decision-making become more challenging in patients with dementia who often experience worsening prognoses, highlighting the urgency of developing effective countermeasures.
View Article and Find Full Text PDFClin Kidney J
January 2025
Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Oxford Road, Manchester, UK.
Background And Hypothesis: Mild cognitive impairment and dementia (CI) are common in patients with CKD. We aim to clarify whether and how CKD and CI coexistence increases adverse health outcomes.
Methods: This retrospective observational cohort study was conducted on CKD patients (stages 3-5) from the TriNetX platform.
Palliat Support Care
January 2025
Unidade Local de Saúde de Santo António, ICBAS Universidade do Porto, Porto, Portugal.
Objectives: More than 50% of patients with dementia visit the emergency department (ED) each year. Patients with dementia experience frequently unrelieved symptoms that can benefit from . Response to needs in the ED can be quite challenging and access to is generally scarce.
View Article and Find Full Text PDFRev Recent Clin Trials
January 2025
Researcher of CNR-IBFM, Secondary Site, Azienda Ospedaliero-Universitaria "Renato Dulbecco" Catanzaro, Italy.
Alzheimer's disease (AD) is a multifactorial pathology, responsible for neurodegenerative disorders which in more than 60% of patients evolve into dementia. Comprehension of the molecular mechanisms underlying the pathology and the development of reliable diagnostic methods have made new and more effective therapies possible. In recent years, in addition to the classic anticholinesterases (AChEs), which can control the clinical symptoms of the disease, compounds able to reduce deposits of amyloid-β (Aβ) and/or tau (τ) protein aggregates, which are disease-modifying therapeutics (DMTs), have been studied.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!